PD-L1 expression, as a regulator of antitumor response, an indicator of T cell infiltration into the tumor, and the target of immune checkpoint inhibitors, has been widely used as a predictive biomarker for immunotherapy in advanced NSCLC4. Here, CD274 is linked to neoplasm.